We are thrilled that APOLLOB successfully met all its major objectives which we believe for the first time validates the hypothesis that TTR silencing by an RNAi therapeutic can be an eective approach for treating the cardiomyopathy of ATTR amyloidosis said Pushkal Garg MD Chief Medical Oicer of Alnylam